



Report #:

IF-824-QSA-TR006-BTL260714-17-09

Page 1 of 2

Title:

## Certificate of Analysis (CoA)



**Date:** 8/5/2026  
**Date Tested:** 7/31/2026  
**Customer:** Repair Aminos  
**Testing material:** CJC-1295 no DAC Ipamorelin  
**Lot Number:** lecp07-26-01  
**Content/Potency:** 10 mg  
**Storage:** R.T.  
**Visual Description:** Small clear vial: white sample, white label, silver crimp, white plastic cap.  
**Labeled as:** CJC-1295 no DAC Ipamorelin  
**Manufacturer:** N/A  
**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test                                         | Method        | Specification                                                                  | Result                                                                                                          |
|----------------------------------------------|---------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| General Appearance                           | USP<br><630>  | white powder                                                                   | white powder                                                                                                    |
| Mass                                         | USP<br><41>   | As recorded                                                                    | 84.6 mg                                                                                                         |
| FTIR Identification and Composition Analysis | USP<br><197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of CJC-1295 no DAC Ipamorelin with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP<br><621>  | Specifications: $\geq 98\%$                                                    | 99.8 %                                                                                                          |
| HPLC Potency Assay                           | USP<br><621>  | Specifications: 90 – 110% of 10 mg                                             | CJC-1295 6.4 mg (64.4 %)<br>Ipamorelin 4.9 mg (48.9 %)                                                          |
| Peptide-to-Excipients Ratio                  | USP<br><1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients)                | 11.3 : 73.3 mg (1:6.5)                                                                                          |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, BS  
Scientist-II  
BTLabs

Escarlet Cabrieles, BS  
Scientist-II  
BTLabs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407

Phone: (561) 625-0133

E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>

IF-824-QSA-TR006


Rev 1.0 January 2025

Title:


# Certificate of Analysis (CoA)



## FTIR ID and Composition Analysis: CJC-1295 no DAC Ipamorelin Lot lecp07-26-01



## HPLC Purity and Potency Assay @ 280 nm: CJC-1295 no DAC Ipamorelin Lot lecp07-26-01



### CJC-1295 no DAC Ipamorelin Lot lecp07-26-01 @ 280 nm

| Peak #: | Retention Time (min) | Area (mAU*s) |
|---------|----------------------|--------------|
| 1       | 4.971                | 1653.4       |
| 2       | 7.156                | 247.3        |